14.01.2016
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Formycon files multiple patent applications for the pharmaceutical formulation and delivery of intraocular VEGF antagonists
DGAP-News: Formycon AG / Key word(s): Patent
Formycon AG: Formycon files multiple patent applications for the
pharmaceutical formulation and delivery of intraocular VEGF antagonists
14.01.2016 / 14:50
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // January 14, 2016
Formycon files multiple patent applications for the pharmaceutical
formulation and delivery of intraocular VEGF antagonists
Munich - Formycon AG, the biosimilars company, today announced that it has
filed already three patent applications relating to the formulation and
intraocular delivery of VEGF antagonists. The first international patent
application related to a silicone-free pre-filled plastic syringe has been
recently published (International Publication Number WO 2015/173260 Al).
VEGF antagonists ranibizumab and aflibercept are commonly used to treat age
dependent eye diseases such as wet macular degeneration. The market size
for intraocular anti-VEGF therapy is rapidly increasing with a current
volume of about USD 6.9 billion.
Pre-filled syringes have many benefits compared to a vial and a separately
provided syringe, such as improved convenience, safety, accuracy,
sterility, and affordability. The use of pre-filled syringes results in
greater dose precision, in a reduction of the potential for needle stick
injuries that can occur while drawing medication from vials, in
pre-measured dosage reducing dosing errors and sterility problems due to
the need to reconstitute medication or draw it into a syringe, and in less
overfilling of the syringe helping to reduce costs by minimising drug
waste.
Silicone-free prefilled plastic syringes containing a VEGF antagonist will
present an innovative way of drug administration for intraocular injection.
Compared to glass syringes this new injection technology offers the
potential for improved safety and convenience for patients and healthcare
professionals as they are resistant to breakage and have a lower weight.
Furthermore, it has been shown that silicone oil from standard glass or
plastic syringes might migrate into the drug solution, cause drug
inactivation, and accumulates in the vitreous cavity after intravitreal
administration of VEGF antagonists.
Dr. Carsten Brockmeyer, CEO of Formycon AG, said "We are pleased to provide
a potential improved way to accurately and safely administer VEGF
antagonist in the eye. Our patent applications cover a broad range of VEGF
antagonist formulations and injection devices. This underlines our mission
to develop high quality biosimilars to treat eye diseases, one of the most
rapidly growing therapeutic areas."
Formycon and its license partner bioeq GmbH, Holzkirchen, Germany, recently
announced the initiation of a pivotal Phase III clinical trial with FYB201,
an investigational biosimilar ranibizumab (Lucentis(R)*).
* Lucentis is a registered trademark of Genentech Inc.
About Formycon:
Formycon is a leading independent pure play developer of biosimilars and
has become a recognized innovator in this field. The company has extensive
experience in the development of complex biological molecules. Formycon's
specialist expertise allows the company to develop high-quality biosimilars
that meet the strict regulatory requirements of highly regulated markets
such as Europe and the United States. Formycon currently has three
biosimilars under development, with further product candidates already
identified. Two biosimilar candidates have been licensed out to Santo
Holding GmbH.
Contact:
Thorsten Schüller
Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 100
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This press release may contain forward-looking statements and information
which are based on our current expectations and certain assumptions.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, performance of the company, development of the products and the
estimates given here. With respect to pipeline products there can be no
guarantees that the products will receive the necessary regulatory
approvals or that they will prove to be commercially successful. Formycon
AG assumes no obligation to update these forward-looking statements or to
correct them in case of developments which differ from those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of Formycon AG. No public offering
of securities of Formycon AG will be made nor is a public offering
intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offer or such solicitation would be
prohibited. This document does not constitute an offer for the sale of
securities in the United States.
---------------------------------------------------------------------------
14.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin; Open Market (Entry
Standard) in Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
429447 14.01.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB